BioAge Labs (NASDAQ:BIOA) Issues Earnings Results, Beats Estimates By $0.07 EPS

BioAge Labs (NASDAQ:BIOA) announced its quarterly earnings results on Wednesday. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.07, Zacks reports. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative return on equity of 30.52% and a negative net margin of 912.26%.

BioAge Labs Trading Up 4.6%

BioAge Labs stock traded up $0.52 during trading on Friday, hitting $11.79. 256,336 shares of the company were exchanged, compared to its average volume of 710,597. The company has a market capitalization of $524.20 million, a P/E ratio of -4.94 and a beta of 0.93. The business’s 50 day moving average is $20.16 and its 200 day moving average is $19.24. BioAge Labs has a 52 week low of $4.25 and a 52 week high of $25.95.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on BIOA shares. Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a report on Friday, July 31st. Wall Street Zen downgraded shares of BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Needham & Company LLC decreased their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Roth Capital restated a “buy” rating and set a $25.00 price objective on shares of BioAge Labs in a report on Friday, July 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, July 21st. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.57.

Hedge Funds Weigh In On BioAge Labs

A number of hedge funds have recently bought and sold shares of BIOA. Price T Rowe Associates Inc. MD increased its stake in BioAge Labs by 24.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock valued at $196,000 after buying an additional 2,917 shares during the last quarter. Barclays PLC boosted its stake in shares of BioAge Labs by 9.3% in the 4th quarter. Barclays PLC now owns 37,780 shares of the company’s stock worth $500,000 after buying an additional 3,222 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of BioAge Labs in the third quarter valued at approximately $27,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after acquiring an additional 5,976 shares in the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.